Evidence map›Paper›PMID 17186341›Full record

ArticleSurgery today2007

Efficacy and limitations of natural killer cell depletion in cyclophosphamide-induced tolerance.

Ichiro Shimizu, Yukihiro Tomita, Shinji Okano, Toshiro Iwai, Takashi Kajiwara, Tatsushi Onzuka, Ryuji Tominaga

Abstract read
PubMed Publisher
In one paragraph

Article in Surgery today, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ichiro ShimizuDepartment of Cardiovascular Surgery, Kyushu University, 3-1-1 Maidashi, Fukuoka 812-8582, Japan.
Yukihiro Tomita
Shinji Okano
Toshiro Iwai
Takashi Kajiwara
Tatsushi Onzuka
Ryuji Tominaga

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe previously developed a cyclophosphamide (CP)-induced tolerance protocol, consisting of an intravenous injection of 1 x 10(8) donor spleen cells (SC) given on day 0 and an intraperitoneal injection of 200 mg/kg CP given on day 2. In the present study, we modified this protocol with natural killer cell (NK) depletion in recipient mice, and evaluated the efficacy of tolerance induction.

methodsWe used B10.D2 (H-2d; IE+) and B10 (H-2b; IE-) mice as both donors and recipients. The recipient mice were treated with donor SC, CP, and donor bone marrow cells (BMCs) with or without NK depletion.

resultsA higher level of mixed chimerism was achieved in the NK-depleted recipients. Survival of both the skin and heart donor grafts was significantly prolonged in the NK-depleted recipients. Donor reactive Vbeta11+ T cells were found at the same level as in untreated control mice. Pretreatment with recipient NK cell depletion was effective in inducing higher levels of donor mixed chimerism; however, permanent engraftment of donor bone marrow was not achieved.

conclusionSurvival of donor grafts was remarkably prolonged in the NK cell-depleted group, but transplantation tolerance could not be induced. Our results suggest that NK cell depletion in CP-induced tolerance conditioning has some effect on the induction of donor-specific tolerance.

Indexed as

ChimerismAnimalsAntibodies, MonoclonalAntigens, SurfaceCyclophosphamideHeart TransplantationImmune ToleranceImmunosuppressive AgentsKiller Cells, NaturalLectins, C-TypeMiceMice, Inbred StrainsModels, AnimalNK Cell Lectin-Like Receptor Subfamily BSkin TransplantationTransplantation ImmunologyAntibodies, MonoclonalAntigens, SurfaceCyclophosphamideImmunosuppressive AgentsLectins, C-TypeNK Cell Lectin-Like Receptor Subfamily B

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.